Home » Agenda » Day 1

Day 1


Patient-centric initiatives across the end-to-end value chain

Copthorne Tara Hotel London Kensington, London, UK

Day 1 - Thursday 1st June 2023


  • What can the industry do to truly integrate patient voice in all aspects of drug development?
  • What can be down to breakdown barriers and imbed Patient-centricity?
  • How can pharma and patient advocates effectively work together?
  • How to ensure that a wider number of voices are heard.
  • New toolsets that are making it possible to include more objective scales and measurement criteria in discussions about what and where to change

Peter Buttle, Patient Advocate, Independent Cancer Patients’ Voice

  • Life prior to diagnosis
  • What took me to my GP
  • Delays in getting treatment at the outset
  • Results & Diagnosis
  • The Early Years
  • Present Day

Alfred Samuels, Patient Advocate, Author, Ambassador/ Member, Cancer Research UK

  • Recognising the gaps in our approach
  • Shifting the patient voice from passive to active
  • Moving toward co-creation, aiming for co-production
  • Bringing patients into the heart of the business

Geoff Rollason, Patient Experience & Service Director Oncology, Pfizer UK

The potential of precision medicine, in particular its power to transform the lives of patients currently living
with Systemic Mastocytosis and other rare diseases will be discussed

Georg Pirmin Meyer, Senior Vice President, Head of International, Blueprint Medicines


Soren Skovlund, Senior Director & Head of Patient Engagement, Patient-Centered Research, Evidera

Ashley Duenas, Senior Research Associate, Patient-Centered Research (PCR) group, Evidera


  • Introduction to patient centric technologies
  • The advantages of decentralized clinical trials and impact on drug development
  • Case studies on use of low volume technologies
  • Implementation challenges and potential solutions

Sally Fischer, Sr. Director & Sr. Fellow, BioAnalytical Sciences/ADT, Development Sciences, Genentech

  • Why is public/patient’s engagement a challenge for basic scientist?
  • Training: Hands on experience
  • Proposed guidelines

Valentina Biasin, Postdoctoral Researcher, Dep’t. of Physiology, Medical University of Graz

  • Clinical research is improved by patients being partners with clinicians and healthcare professionals, rather than passive recipients of healthcare.
  • Involve patients in clinical research, clinical trials, clinical/academic units , tissue banks
  • Putting the patient perspective and helping to improve clinical research.
  • Leads to better recruitment to clinical trials and faster improvements in treatments and outcomes for all cancer patients.
  • Empower patients to speak as equals with the professionals as patient advocates through education

Angela King, Independent Patient Advocate, Independent Cancer Patients’ Voice


  • Why and how should we reward and recognise the contribution of our patient and public partners?
  • The risks and benefits of offering payment/incentives for patient and public involvement.
  • Involvement at Prostate Cancer UK: our reward and recognition journey.

Steven Towndrow, Patient and Community Involvement Manager, Prostate Cancer UK

  • What does it mean to Co Create and Co Deliver
  • Why is it Vital across the NHS, Health and Social
  • How this is achieved

Julie Jaye Charles, Board Advisor & Lead on Advocacy & Co Production, NELFT NHS Foundation Trust

  • Current system and the gaps and challenges that exist in patient engagement and the generation and use of PED
  • Co-creation of the PFMD “Global PED Navigator” and the benefits it provides to all stakeholders.
  • The need for a roadmap to navigate the complex landscape of patient engagement and PED
  • Why Patient Engagement and PED integration is the future of healthcare

Carole Scrafton, CEO & Co-Founder, FibroFlutters

Hayley Chapman, Senior Program Director, The Synergist

Scroll to Top